EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC
Status:
Unknown status
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The aim of this study was to compare the efficacy of EGFR-TKIs(Epidermal Growth Factor
Receptor-Tyrosine Kinase Inhibitors) treatment plus concurrent chemotherapy versus sequential
treatment with EGFR-TKIs and chemotherapy in patients with EGFR(Epidermal Growth Factor
Receptor)-mutant non-small-cell lung cancer (NSCLC).